149 related articles for article (PubMed ID: 17826092)
1. Optimization of triarylimidazoles for Tie2: influence of conformation on potency.
Johnson NW; Semones M; Adams JL; Hansbury M; Winkler J
Bioorg Med Chem Lett; 2007 Oct; 17(20):5514-7. PubMed ID: 17826092
[TBL] [Abstract][Full Text] [Related]
2. Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable.
Buttar D; Edge M; Emery SC; Fitzek M; Forder C; Griffen A; Hayter B; Hayward CF; Hopcroft PJ; Luke RW; Page K; Stawpert J; Wright A
Bioorg Med Chem Lett; 2008 Aug; 18(16):4723-6. PubMed ID: 18676144
[TBL] [Abstract][Full Text] [Related]
3. Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo.
Luke RW; Ballard P; Buttar D; Campbell L; Curwen J; Emery SC; Griffen AM; Hassall L; Hayter BR; Jones CD; McCoull W; Mellor M; Swain ML; Tucker JA
Bioorg Med Chem Lett; 2009 Dec; 19(23):6670-4. PubMed ID: 19854647
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases.
Dandu R; Zulli AL; Bacon ER; Underiner T; Robinson C; Chang H; Miknyoczki S; Grobelny J; Ruggeri BA; Yang S; Albom MS; Angeles TS; Aimone LD; Hudkins RL
Bioorg Med Chem Lett; 2008 Mar; 18(6):1916-21. PubMed ID: 18308565
[TBL] [Abstract][Full Text] [Related]
5. Tri- and tetrasubstituted imidazoles as p38α mitogen-activated protein kinase inhibitors.
Laufer S; Hauser D; Stegmiller T; Bracht C; Ruff K; Schattel V; Albrecht W; Koch P
Bioorg Med Chem Lett; 2010 Nov; 20(22):6671-5. PubMed ID: 20934337
[TBL] [Abstract][Full Text] [Related]
6. 8-THP-DHI analogs as potent Type I dual TIE-2/VEGF-R2 receptor tyrosine kinase inhibitors.
Hudkins RL; Zulli AL; Underiner TL; Angeles TS; Aimone LD; Meyer SL; Pauletti D; Chang H; Fedorov EV; Almo SC; Fedorov AA; Ruggeri BA
Bioorg Med Chem Lett; 2010 Jun; 20(11):3356-60. PubMed ID: 20430619
[TBL] [Abstract][Full Text] [Related]
7. Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase.
Cee VJ; Cheng AC; Romero K; Bellon S; Mohr C; Whittington DA; Bak A; Bready J; Caenepeel S; Coxon A; Deak HL; Fretland J; Gu Y; Hodous BL; Huang X; Kim JL; Lin J; Long AM; Nguyen H; Olivieri PR; Patel VF; Wang L; Zhou Y; Hughes P; Geuns-Meyer S
Bioorg Med Chem Lett; 2009 Jan; 19(2):424-7. PubMed ID: 19062275
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase.
Kim DK; Lim JH; Lee JA; Dewang PM
Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921
[TBL] [Abstract][Full Text] [Related]
9. Pyridinylimidazole inhibitors of Tie2 kinase.
Semones M; Feng Y; Johnson N; Adams JL; Winkler J; Hansbury M
Bioorg Med Chem Lett; 2007 Sep; 17(17):4756-60. PubMed ID: 17618114
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.
Laufer SA; Hauser DR; Domeyer DM; Kinkel K; Liedtke AJ
J Med Chem; 2008 Jul; 51(14):4122-49. PubMed ID: 18578517
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of 7-hydroxy-1H-benzoimidazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.
Shin D; Lee SC; Heo YS; Lee WY; Cho YS; Kim YE; Hyun YL; Cho JM; Lee YS; Ro S
Bioorg Med Chem Lett; 2007 Oct; 17(20):5686-9. PubMed ID: 17764934
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors.
Hodous BL; Geuns-Meyer SD; Hughes PE; Albrecht BK; Bellon S; Caenepeel S; Cee VJ; Chaffee SC; Emery M; Fretland J; Gallant P; Gu Y; Johnson RE; Kim JL; Long AM; Morrison M; Olivieri PR; Patel VF; Polverino A; Rose P; Wang L; Zhao H
Bioorg Med Chem Lett; 2007 May; 17(10):2886-9. PubMed ID: 17350837
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2.
Xie QQ; Xie HZ; Ren JX; Li LL; Yang SY
J Mol Graph Model; 2009 Feb; 27(6):751-8. PubMed ID: 19138543
[TBL] [Abstract][Full Text] [Related]
14. Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.
Hodous BL; Geuns-Meyer SD; Hughes PE; Albrecht BK; Bellon S; Bready J; Caenepeel S; Cee VJ; Chaffee SC; Coxon A; Emery M; Fretland J; Gallant P; Gu Y; Hoffman D; Johnson RE; Kendall R; Kim JL; Long AM; Morrison M; Olivieri PR; Patel VF; Polverino A; Rose P; Tempest P; Wang L; Whittington DA; Zhao H
J Med Chem; 2007 Feb; 50(4):611-26. PubMed ID: 17253678
[TBL] [Abstract][Full Text] [Related]
15. 3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family.
Cao H; Zhang H; Zheng X; Gao D
J Mol Graph Model; 2007 Jul; 26(1):236-45. PubMed ID: 17293140
[TBL] [Abstract][Full Text] [Related]
16. Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).
Lafleur K; Huang D; Zhou T; Caflisch A; Nevado C
J Med Chem; 2009 Oct; 52(20):6433-46. PubMed ID: 19788238
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of benzenesulfonamide-substituted 4-(6-alkylpyridin-2-yl)-5-(quinoxalin-6-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
Kim DK; Jung SH; Lee HS; Dewang PM
Eur J Med Chem; 2009 Feb; 44(2):568-76. PubMed ID: 18467006
[TBL] [Abstract][Full Text] [Related]
18. Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors.
Jessop TC; Tarver JE; Carlsen M; Xu A; Healy JP; Heim-Riether A; Fu Q; Taylor JA; Augeri DJ; Shen M; Stouch TR; Swanson RV; Tari LW; Hunter M; Hoffman I; Keyes PE; Yu XC; Miranda M; Liu Q; Swaffield JC; David Kimball S; Nouraldeen A; Wilson AG; Foushee AM; Jhaver K; Finch R; Anderson S; Oravecz T; Carson KG
Bioorg Med Chem Lett; 2009 Dec; 19(23):6784-7. PubMed ID: 19836232
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological activity of anticoccidial agents: 5,6-diarylimidazo[2,1-b][1,3]thiazoles.
Scribner A; Meitz S; Fisher M; Wyvratt M; Leavitt P; Liberator P; Gurnett A; Brown C; Mathew J; Thompson D; Schmatz D; Biftu T
Bioorg Med Chem Lett; 2008 Oct; 18(19):5263-7. PubMed ID: 18789686
[TBL] [Abstract][Full Text] [Related]
20. Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors.
Dai Y; Hartandi K; Soni NB; Pease LJ; Reuter DR; Olson AM; Osterling DJ; Doktor SZ; Albert DH; Bouska JJ; Glaser KB; Marcotte PA; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2008 Jan; 18(1):386-90. PubMed ID: 18023347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
